CweL trial design. by Stanley Carries (21172287)

“…Compared to controls, there was a non-significant increase in psychological wellbeing (β = 3.14, <i>p = </i>0.319). …”

Participant Flow. by Stanley Carries (21172287)

“…Compared to controls, there was a non-significant increase in psychological wellbeing (β = 3.14, <i>p = </i>0.319). …”

Economic cost composition by arm and outcomes. by Stanley Carries (21172287)

“…Compared to controls, there was a non-significant increase in psychological wellbeing (β = 3.14, <i>p = </i>0.319). …”

Summary map of all contacts with statistically significant SVM classifications. by Alexander P. Rockhill (6053618)

“…Yellow indicates an increase in time-frequency clusters during number trials versus inter-trial intervals while blue indicates a decrease in time-frequency clusters. …”

<i>SLC2A2</i> is essential for liver differentiation in developing vertebrates by Yejin Kim (740789)

“…The mRNA expression levels were normalized to β-actin. A significant increase (p-value < 0.001, ***) in igf1r expression was observed in <i>SLC2A2</i> MO-injected embryos compared to the control group. …”

Statins induced flatter neuronal somas. by Shuk C. Tsoi (21192243)

<b> </b> Rate of brain weight to body weight in different experimental groups. AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate.... by Atefeh Sadeghi (21253051)

“…AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate. …”

Two magnifications SEM images for the produced SiO₂ nanoparticles. by Nasser A. M. Barakat (11705885)

Subjects:

Schematic presentation of mechanism of anti-cancer activity of ATO and GCB combination in breast cancer cells. by Farshid Maleki (20521649)

Subjects:

XRD pattern for the prepared titanium oxide nanofibers. by Nasser A. M. Barakat (11705885)

Subjects:

Plasticity limit (%) of pristine and modified Egyptian kaolin. by Nasser A. M. Barakat (11705885)

Subjects:

Thermal gravimetric analyses and the first derivative for the obtained data for the PVA; (A and B) and TiO₂; (C and D) compared with the pristine kaolin. by Nasser A. M. Barakat (11705885)

Subjects:

Chemical composition (%) of the Egyptian clay [9]. by Nasser A. M. Barakat (11705885)

Subjects:

Compression strength of pristine and modified Egyptian kaolin sintered at two temperatures: 900 and 1050 °C. by Nasser A. M. Barakat (11705885)

Subjects:

Two magnifications SEM; (A and B) and TEM (C and D) images for the produced TiO₂ nanofibers. by Nasser A. M. Barakat (11705885)

Subjects:

Apparent density of pristine and modified Egyptian kaolin sintered at two temperatures: 900 and 1050 °C. by Nasser A. M. Barakat (11705885)

Subjects:

Water absorption of pristine and modified Egyptian kaolin sintered at two temperatures: 900 and 1050 °C. by Nasser A. M. Barakat (11705885)

Subjects:

Trypan blue dye exclusion assay for cell viability evaluation (% of control). by Farshid Maleki (20521649)

Subjects:

Percentage change in the apparent density of pristine and modified Egyptian kaolin sintered at 1050 °C for 4 successive cycles. by Nasser A. M. Barakat (11705885)

Subjects:

Porosity of pristine and modified Egyptian kaolin sintered at two temperatures: 900 and 1050 °C. by Nasser A. M. Barakat (11705885)

Subjects: